{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:14:57Z","timestamp":1740147297889,"version":"3.37.3"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Polycythaemia vera (PV) is a Philadelphia-negative myeloproliferative neoplasm, typically driven by acquired <jats:italic>JAK2<\/jats:italic> mutation and characterised by elevated red cell mass and increased risk of thrombotic events. Patients are managed with phlebotomy to maintain haematocrit (Hct)\u2009&lt;\u20090.45, and patients stratified as \u2018high risk\u2019 for thrombosis are additionally treated with cytoreductive agents to attain this target.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Study<\/jats:title>\n                <jats:p>This analysis of newly diagnosed <jats:italic>JAK2<\/jats:italic> mutant PV patients (<jats:italic>n<\/jats:italic>\u2009=\u200950) over 2 years aimed to determine how effectively patients attained and maintained target Hct according to recommended practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We found that patients spent the majority of time in target Hct range. Findings are supportive of current management guidelines.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11845-023-03510-7","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T06:01:31Z","timestamp":1694152891000},"page":"833-836","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of real-world data demonstrating the efficacy of current management of polycythaemia vera in attaining and maintaining therapeutic haematocrit"],"prefix":"10.1007","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6435-8699","authenticated-orcid":false,"given":"Frances D.","family":"Buckley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Brass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Catherwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Frances","family":"McMullin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"issue":"10","key":"3510_CR1","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythaeia vera. J Clin Oncol 23(10):2224\u20132232. https:\/\/doi.org\/10.1200\/JCO.2005.07.062","journal-title":"J Clin Oncol"},{"key":"3510_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G et al (2013) Cardiovascular events and intensity of treatment in polycythaemia vera. N Engl J Med 368:22\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1208500","journal-title":"N Engl J Med"},{"key":"3510_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15648","author":"MF McMullin","year":"2018","unstructured":"McMullin MF, Harrison AS, Cargo C et al (2018) A guideline for the diagnosis and management of polycythaemia vera. A BSH guideline. B J Haem. https:\/\/doi.org\/10.1111\/bjh.15648","journal-title":"B J Haem"},{"key":"3510_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41408-017-0042-7","volume":"8","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Vannucchi AM, Barbui T (2018) Polycythaemia vera treatment algorithm 2018. Blood Cancer J 8:3. https:\/\/doi.org\/10.1038\/s41408-017-0042-7","journal-title":"Blood Cancer J"},{"key":"3510_CR5","doi-asserted-by":"publisher","unstructured":"Marchetti M, Vannucchi AM, Griesshammer M et al (2022) Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol 9(4):e301\u2013e311. https:\/\/doi.org\/10.1016\/S2352-3026(22)00046-1","DOI":"10.1016\/S2352-3026(22)00046-1"},{"key":"3510_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40164-018-0107-8","volume":"7","author":"D Paranagama","year":"2018","unstructured":"Paranagama D, Colucci P, Evans KA et al (2018) Are patients with high-risk polycythaemia vera receiving cytoreductive medications? A retrospective analysis of real-world data. Exp Hematol Oncol 7:16. https:\/\/doi.org\/10.1186\/s40164-018-0107-8","journal-title":"Exp Hematol Oncol"},{"key":"3510_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30373-2","author":"T Barbui","year":"2021","unstructured":"Barbui T, Vannucchi A, De Stefano V et al (2021) Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. https:\/\/doi.org\/10.1016\/S2352-3026(20)30373-2","journal-title":"Lancet Haematol"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-023-03510-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-023-03510-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-023-03510-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T03:59:38Z","timestamp":1711339178000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-023-03510-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":7,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["3510"],"URL":"https:\/\/doi.org\/10.1007\/s11845-023-03510-7","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"type":"print","value":"0021-1265"},{"type":"electronic","value":"1863-4362"}],"subject":[],"published":{"date-parts":[[2023,9,8]]},"assertion":[{"value":"20 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not required from participants included in the study, in accordance with the guidance of the NHS Health Research Authority.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"M. F. M. has received consulting fees and payment for educational\/speaker activities from Novartis and Sierra Oncology, has obtained institutional support for trial funding from AOP and BMS, and has participated in an unpaid scientific advisory board for MPN Voice. F. B. has participated in unpaid advisory board with Novartis. C. A. declares that she has no conflict of interest. D. B. declares that she has no conflict of interest. M. C. declares that he has no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}